Insider Trading Arrangements	3 Months Ended	9 Months Ended
	Jun. 30, 2023 shares	Jun. 30, 2023 shares
Trading Arrangements, by Individual
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Michael Garrison [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		On May 5, 2023, Michael Garrison, our executive vice president and president of the Medical segment of BD, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Garrison’s plan is for (i) the exercise of up to 15,467 stock appreciation rights (“SARs”) at various exercise prices, net of shares withheld to satisfy applicable taxes, (ii) the sale of up to 1,712 shares of BD’s common stock, (iii) the sale of up to 1,531 shares of BD’s common stock upon the vesting of time vested units (“TVUs”), net of shares withheld to satisfy applicable taxes, and (iv) the sale of up to 2,033 shares of BD’s common stock upon the vesting of performance units, subject to the final payout factor and net of shares withheld to satisfy applicable taxes. The foregoing exercises or sales will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold and August 31, 2024.
Name	Michael Garrison
Title	executive vice president and president of the Medical segment
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	May 5, 2023
Termination Date	August 31, 2024
Arrangement Duration	484 days
David Hickey [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		On May 12, 2023, David Hickey, our executive vice president and president of the Life Sciences segment of BD, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Hickey’s plan is for (i) the exercise of up to 3,883 SARs at various exercise prices, net of shares withheld to satisfy applicable taxes, and (ii) the sale of up to 948 shares of BD’s common stock. The foregoing exercises or sales will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold and August 6, 2024.
Name	David Hickey
Title	executive vice president and president of the Life Sciences segment
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	May 12, 2023
Termination Date	August 6, 2024
Arrangement Duration	452 days
Catherine Burzik [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		On May 24, 2023, Catherine Burzik, a member of our board of directors, on behalf of the Catherine and Francis Burzik Foundation, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Ms. Burzik’s plan is for the sale of up to 800 shares of BD’s common stock. The sales will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold and September 30, 2024.
Name	Catherine Burzik
Title	member of our board of directors
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	May 24, 2023
Termination Date	September 30, 2024
Arrangement Duration	495 days
Aggregate Available	800	800
Richard Byrd [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		On May 25, 2023, Richard Byrd, our executive vice president and president of the Interventional segment of BD adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Byrd’s plan is for (i) the exercise of up to 9,058 SARs at various exercise prices, net of shares withheld to satisfy applicable taxes, (ii) the sale of up to 1,262 shares of BD’s common stock upon the vesting of TVUs, net of shares withheld to satisfy applicable taxes, and (iii) the sale of up to 1,874 shares of BD’s common stock upon the vesting of performance units, subject to the final payout factor and net of shares withheld to satisfy applicable taxes. The foregoing exercises or sales will be made in accordance with the prices and formulas set forth in the plan and such plan terminates on the earlier of the date all the shares under the plan are sold and May 25, 2024.
Name	Richard Byrd
Title	executive vice president and president of the Interventional segment
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	May 25, 2023
Termination Date	May 25, 2024
Arrangement Duration	366 days
Michael Garrison Trading Arrangement, Stock Appreciation Rights [Member] | Michael Garrison [Member]
Trading Arrangements, by Individual
Aggregate Available	15,467	15,467
Michael Garrison, Trading Arrangement, Common Stock [Member] | Michael Garrison [Member]
Trading Arrangements, by Individual
Aggregate Available	1,712	1,712
Michael Garrison, Trading Arrangement, Common Stock Upon The Vesting Of Time Vested Units [Member] | Michael Garrison [Member]
Trading Arrangements, by Individual
Aggregate Available	1,531	1,531
Michael Garrison, Trading Arrangement, Common Stock Upon The Vesting Of Performance Units [Member] | Michael Garrison [Member]
Trading Arrangements, by Individual
Aggregate Available	2,033	2,033
David Hickey, Trading Arrangement, Stock Appreciation Rights [Member] | David Hickey [Member]
Trading Arrangements, by Individual
Aggregate Available	3,883	3,883
David Hickey, Trading Arrangement, Common Stock [Member] | David Hickey [Member]
Trading Arrangements, by Individual
Aggregate Available	948	948
Richard Byrd, Trading Arrangement, Stock Appreciation Rights [Member] | Richard Byrd [Member]
Trading Arrangements, by Individual
Aggregate Available	9,058	9,058
Richard Byrd, Trading Arrangement, Common Stock Upon The Vesting Of Time Vested Units [Member] | Richard Byrd [Member]
Trading Arrangements, by Individual
Aggregate Available	1,262	1,262
Richard Byrd, Trading Arrangement, Common Stock Upon The Vesting Of Performance Units [Member] | Richard Byrd [Member]
Trading Arrangements, by Individual
Aggregate Available	1,874	1,874